3:44 PM · 10 September 2020

Quest Diagnostics stock is rising on upbeat guidance

Quest Diagnostics (DGX.US) stock rose over 3% after the medical lab operator lifted its full-year guidance and profit outlook, citing a faster-than-anticipated recovery in testing volumes through the end of August. Company now expects adjusted earnings of $7.42 to $8.92 per share, up from the prior range of $5.66 to $7.66 a share. The current consensus estimate is $8.51 a share. The company raised its 2020 guidance range for revenue to $8.4 billion to $8.8 billion from $8.0 billion to $8.6 billion, compared with the FactSet consensus of $8.69 billion.
Quest Diagnostics (DGX.US) - stock managed to bounce off the 200 MA (red line) and rally. Should upbeat moods prevail, resistance at $119 may come into play. This level is also additionally strengthened by 50 MA (green line). However, should market sentiment change, the nearest support is located at $104.00. Source: xStation5
5 June 2026, 3:45 PM

NFP: A turning point for the dollar and the start of a stock market correction?

5 June 2026, 2:49 PM

US Open: Wall Street slides amid semiconductor stocks sell-off 📌Intel down 6%

5 June 2026, 12:44 PM

Market Wrap: SAP bucks tech sell-off, SpaceX blocked from S&P 500 entry (05.06.2026)

5 June 2026, 12:10 PM

Lululemon Athletica slumps 14% after earnings amid weak North America sales 📉

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits